cfDNA blood collection tube market seen rising on diagnostics demand

The cell-free DNA blood collection tube market is projected to grow from $1.33 billion in 2025 to $2.49 billion by 2030, driven by liquid biopsy use in cancer, prenatal testing and broader diagnostic adoption. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth through the forecast period.

Why it matters: - cfDNA blood collection tubes support non-invasive testing that can improve decisions in cancer, prenatal screening and other diagnostics. - The market’s projected rise signals broader adoption of liquid biopsy and advanced molecular testing across healthcare systems. - Growth also reflects rising demand for sample-preservation tools that help protect test accuracy from collection to analysis.

What happened: - The Business Research Company released a 2026 market report on the global cell-free DNA blood collection tube market. - The market was valued at $1.33 billion in 2025. - The market is projected to reach $1.51 billion in 2026. - The report forecasts the market will grow to $2.49 billion by 2030. - The report cites a 13.6% CAGR from 2025 to 2026 and a 13.3% CAGR through 2030. - The report also provides a free sample and the full market report.

The details: - A cfDNA blood collection tube is designed to collect, preserve and transport blood samples for cfDNA analysis. - The tubes use proprietary preservatives to reduce nucleic acid degradation and limit contamination from genomic DNA released by white blood cells. - The preserved samples are used for liquid biopsies, prenatal genetic screening and cancer diagnostics. - The report points to growth drivers including prenatal diagnostics, cfDNA use in cancer detection, research adoption, laboratory automation and more diagnostic facilities. - The forecast period includes expected support from better blood tube preservatives, artificial intelligence in diagnostics, liquid biopsy growth, more clinical trials and rising demand in emerging economies. - The report highlights trends in improved sample preservation, integration with liquid biopsy platforms, standardized collection protocols, automation in sample handling and tubes built for greater stability. - Respiratory conditions are cited as a demand driver because non-invasive cfDNA testing can help detect genetic mutations, monitor disease progression and assess treatment response. - CDC data showed an estimated 17,000 to 34,000 U.S. hospitalizations from RSV between October and November 2024. - Cancer incidence is also boosting demand because cfDNA tubes support liquid biopsies that can detect tumor mutations, track progression, evaluate treatment effectiveness and identify resistance mutations. - National Cancer Institute projections from May 2024 estimate U.S. cancer survivors will rise to 26 million by 2040 from 18.1 million in 2022.

Between the lines: - The report frames cfDNA tubes as part of a larger shift toward less invasive diagnostics that can replace or reduce tissue biopsies. - Rising respiratory disease and cancer burdens create more use cases for blood-based testing, even as diagnostics get more automated and data-driven. - The combination of clinical demand and technology upgrades suggests the market is moving from niche use toward broader routine adoption.

What’s next: - North America held the largest market share in 2025, supported by strong healthcare infrastructure and early adoption of advanced diagnostics. - Asia-Pacific is expected to grow fastest during the forecast period as healthcare investment, diagnostic centers and genetic testing awareness expand. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa, pointing to wider global expansion opportunities. - The report’s 2026 package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, key technology analysis and updated graphics.

The bottom line: - cfDNA blood collection tubes are becoming a key enabling technology for liquid biopsy and other molecular tests, with strong demand growth projected through 2030.